Sectors
ICCC
ImmuCell Corporation
11.02
3 x 10.88
1 x 11.07
bid
ask
+
0.27
2.51%
1 @ 04:00 PM
10.81 -0.21 (1.91%)
| Ytd | 79.19% | |
| 1y | 78.32% |
10.62
day range
11.15
4.52
52 week range
12.10
| Open | 10.98 | Prev Close | 10.75 | Low | 10.62 | High | 11.15 | Mkt Cap | 99.70M |
| Vol | 33.55K | Avg Vol | 29.58K | EPS | -0.06 | P/E | -183.67 | Forward P/E | -42.82 |
| Beta | 0.54 | Short Ratio | 0.23 | Inst. Own | 14.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 10.40 | 200-d Avg | 7.56 | 1yr Est | 14.00 |
ICCC News
globenewswire.com
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” o
benzinga.com
ImmuCell Q2 Total Product Sales Rises 12%
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health